Discover insightful articles on health, wellness, and the habits that support a longer, stronger life.
Showing 25 to 34 of 34 articles
A focused look at why ER-100’s clinical protocol looks the way it does Life Biosciences’ ER-100 program—cleared by the FDA to begin a Phase 1 study in early 202...
What happened and why it matters now Life Biosciences announced U.S. Food and Drug Administration (FDA) clearance of an investigational new drug (IND) applicati...
Why 2026 feels like a turning point for longevity clinics Growth in private longevity clinics, expanded telemedicine prescribing flexibilities, and a simultaneo...
Why the idea of a “staged” evidence pathway matters now Over the past 18 months regulators and sponsors have produced a set of operational precedents that, take...
Regulatory momentum: two complementary shifts In the first four months of 2026 the FDA published a draft guidance that explicitly endorses practical use of Baye...
Summary In the last 12–18 months U.S. geroscience has moved from isolated pilot projects toward a coordinated translational stack: new center grants and cores,...
Where the human data stand Over the past two years a small but growing set of randomized and pilot human trials has begun to test whether rapamycin or related "...
Why tissue delivery and better biomarkers matter now Over the past 18 months a distinct translational pathway for geroscience has gained momentum: local deliver...
Summary The U.S. federal court decision and subsequent FDA action that vacated the 2024 LDT final rule has immediate, practical consequences for how longevity a...
Life Biosciences’ ER-100 IND clearance: what happened On Jan. 28, 2026, Life Biosciences announced that the U.S. Food and Drug Administration had cleared an inv...
Join the mailing list
Be the first to know when fresh articles are published.